Form 8-K - Current report:
SEC Accession No. 0001193125-22-167430
Filing Date
2022-06-03
Accepted
2022-06-03 17:15:57
Documents
13
Period of Report
2022-06-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d525291d8k.htm   iXBRL 8-K 50177
2 EX-2.1 d525291dex21.htm EX-2.1 519358
  Complete submission text file 0001193125-22-167430.txt   827773

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tptx-20220602.xsd EX-101.SCH 2877
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tptx-20220602_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tptx-20220602_pre.xml EX-101.PRE 11275
7 EXTRACTED XBRL INSTANCE DOCUMENT d525291d8k_htm.xml XML 3359
Mailing Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121
Business Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121 858-926-5251
Turning Point Therapeutics, Inc. (Filer) CIK: 0001595893 (see all company filings)

EIN.: 463826166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38871 | Film No.: 22995716
SIC: 2834 Pharmaceutical Preparations